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Scientific Abstract  
 There is significant variation in prescriptions among countries in clinical practice for the 
treatment of autism spectrum disorder (ASD). It has also been suggested that many people with 
mental health disorders in low/middle-income countries do not receive adequate treatment. 
Hence, this study investigated psychopharmacological treatment patterns for ASD in thirty 
countries and the association between the country’s income and ASD prescription rates.  
The IMS Prescribing Insights database was used to investigate the prescription patterns 
for ASD treatment in 2007-2012. Data were obtained from 30 countries in the continents of 
Europe, Asia, Oceania, Central America, South America and Africa. The Gross Domestic 
Product (GDP) per capita was used as a proxy for the country’s income. Spearman correlation 
was used to examine the association between prescription rate and GDP per capita. 
The highest prescription rate was found in Europe (1.34-36.36/10,000) while the lowest 
prescription rates were found in Asian countries, such as Turkey, Indonesia, Saudi Arabia and 
Pakistan (0.04-0.82/10,000). The most common prescribed drug for ASD treatment in most of 
the countries was risperidone, but antidepressants and anti-epileptic drugs were also frequently 
prescribed. There was a significant positive correlation between GDP per capita and prescription 
rate (Spearman ρ=0.60; p=0.0011; 95%CI 0.27-0.81), that is, the higher the GDP per capita, the 
higher the prescription rate.  
There are marked international differences in prescription rates for ASD, and this is 
partially accounted by economic factors. Future research should combine more data for ASD 
treatment to inform on the disparity of psychopharmacological treatment between countries.  
(249 words) 
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Lay Abstract 
There is wide variation in prescriptions among countries in clinical practice for the 
treatment of autism spectrum disorder (ASD). Many people with mental health disorders living 
in countries classified as low/middle income do not receive adequate treatment. Therefore, this 
study investigated psychopharmacological treatment patterns for ASD in thirty countries and the 
association between the country’s income and ASD prescription rates.  
An international healthcare information database (The IMS Prescribing Insights database) 
was used to investigate the prescription patterns for ASD treatment in 2007-2012. Data were 
obtained from 30 countries in the continents of Europe, Asia, Oceania, Central America, South 
America and Africa. The Gross Domestic Product (GDP) per capita was used as an indicator for 
the country’s income. Spearman correlation, a statistical model, was used to examine the 
association between prescription rate and GDP per capita. 
The highest prescription rate was found in Europe (1.34-36.36/10,000) while the lowest 
prescription rates were found in Asian countries, such as Turkey, Indonesia, Saudi Arabia and 
Pakistan (0.04-0.82/10,000). The most common prescribed drug for ASD treatment in most of 
the countries was risperidone, but antidepressants and anti-epileptic drugs were also frequently 
prescribed. The result implied the higher the GDP per capita, the higher the prescription rate 
between countries.  
There are marked international differences in prescription rates for ASD, and this is 
partially accounted by economic factors. Future research should combine more data for ASD 
treatment to develop an understand of the disparity of psychopharmacological treatment between 
countries.  
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(242 words) 
Introduction  
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterised by impaired 
social and communicative behaviour as well as rigid and stereotyped patterns of behaviour 
(American Psychiatric Association, 1994; World Health Organization). ASD is often comorbid 
in many individuals with mental health conditions including anxiety and mood disorders, 
attention-deficit hyperactivity disorder (ADHD), seizure disorder, sleep disorder and learning 
disabilities (Bradley & Bolton, 2006; MacNeil, Lopes, & Minnes, 2009; Matson & Neal, 2009; 
Simonoff et al., 2008; Souders et al., 2009). Recent epidemiological studies report a prevalence 
of ASD of approximately 1.1% in children and adolescents in the United Kingdom (UK) and the 
United States (US) (Baird et al., 2006; Kogan et al., 2009), but the prevalence varies in different 
countries and across studies (Elsabbagh et al., 2012). Approximately 70% of individuals with 
ASD suffer from additional mental conditions (Simonoff et al., 2008).   
The clinical management of ASD aims to maximise the affected individual’s functional 
independence and quality of life, and to mitigate carer’s distress and burden (Carbone, Farley, & 
Do, 2010; Myers, Johnson, & American Academy of Pediatrics Council on Children With 
Disabilities, 2007) by minimising core symptoms, lowering the impact of associated mental 
health symptoms and reducing maladaptive behaviours (Cadman et al., 2012). It includes 
educational and behavioural programmes and pharmacological treatment as an adjunct in the 
management of ASD (Myers et al., 2007). There are currently no highly effective 
pharmacological treatments for the core symptoms of ASD, therefore current approaches target 
the minimisation of comorbid symptoms. Currently, however, there are limited practical 
guidelines for the pharmacological treatments of associated symptoms in children and 
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adolescents with ASD (Frazier et al., 2011). In the US, only risperidone and aripiprazole are 
approved by the Food and Drug Administration (FDA) for the treatment of irritability in children 
with ASD (Marcus et al., 2009; Owen et al., 2009; Shea et al., 2004). In other western countries, 
risperidone is also approved for the indication of behavioural disturbance among children and 
adolescents with ASD by the European Medicines Agency (EMA), the Medicines and 
Healthcare Products Regulatory Agency (MHRA) of the UK, and the Australian Therapeutic 
Goods Administration (TGA) (European Medicines Agency, 2007; World Health Organization, 
2013). Despite insufficient evidence on efficacy and long-term safety of psychotropic drugs for 
ASD treatment, various medications have been used for ASD treatment in clinical practice such 
as α-adrenergic agents, β blockers, mood stabilisers (or antiepileptics) and  antipsychotics 
(Hollander, Phillips, & Yeh, 2003; McPheeters et al., 2011; Myers et al., 2007; Rosenberg et al., 
2010).  
Previous studies have estimated that approximately 27% to 60% of children and adolescents 
received at least one medication for ASD treatment in the US and Canada (Coury et al., 2012; 
Frazier et al., 2011; Mandell et al., 2008). In the UK, a study using a primary care database 
reported approximately 29% (1,619/5,651) of young people aged 0-24 years with ASD received 
psychotropic drugs; and the commonly prescribed drug classes were sleep medications (9.7%), 
stimulants (7.9%), and antipsychotics (7.3%) (Murray et al., 2013). Although previous studies 
have demonstrated the prescription patterns of ASD treatment in the US and the UK, the 
generalisability of the findings to other countries is unknown. This is of relevance due to 
geographic and cultural differences, as well as potential variations in clinical practice [22]. A 
face-to-face interview survey study conducted by the World Health Organisation (WHO) in 17 
countries showed that the proportion of patients with mental health disorders (e.g. anxiety, mood 
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and substance disorders) receiving either pharmacotherapy (≥1 month of a medication, plus ≥ 4 
visits to medical doctor) or psychotherapy (≥ 8 visits with any professional) was smaller in low 
and middle-income countries as compared with high-income countries (Wang et al., 2007). In 
addition, it suggested that the majority of people with mental health disorders in low/middle 
income countries do not receive the treatment that they need (Lund et al., 2012). In our previous 
work, we demonstrated significant variation in psychopharmacological prescription  patterns 
between 2010 and 2012 in children and adolescents with ASD across ten countries (Hsia et al., 
2013). However, we did not investigate the extent to which a country’s income is associated with 
variation in drug treatment. Also to date, there are very limited cross-national studies on ASD 
treatment available. Therefore, we conducted a descriptive comparison of prescription rates in 30 
countries that previously had no published data. We investigated whether a country’s income 
was associated with ASD treatment.   
Method 
Data source 
This was a descriptive study using the IMS Prescribing Insights (MIDAS) database to investigate 
prescriptions issued for patients with a diagnosis of ASD in 30 countries. The IMS MIDAS 
database is an audit drawn from a representative sample of practitioners in each country and 
contains diagnoses and prescription data from different countries (Wong & Murray, 2005). The 
prescription data of sampled doctors were adjusted according to different stratification methods 
(see Table 1), and a projected national total of prescriptions data per year was calculated for each 
country. Table 1 summarises the details of data collection including the number of doctors 
involved, stratification methods, and reporting time for each country. Previous studies have used 
the MIDAS database to investigate the prescription trends and patterns of psychotropic 
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prescriptions (Balkrishnan, Phatak, Gleim, & Karve, 2009; Livermore et al., 2006; Wong, 
Murray, Camilleri-Novak, & Stephens, 2004). Therefore, this database is suitable for 
investigating the prescription patterns at a global level.  
Study population  
Prescriptions for patients with a diagnosis of ASD were identified using International 
Classification of Disease (ICD), tenth revision codes under F84 (Pervasive Development 
Disorder; PDD) (Supplementary Online Material 1) between January 2007 and December 2012 
(study period) in the IMS MIDAS database. Data were obtained from 12 European countries 
(Austria, Belgium, Netherlands, Finland, Ireland, Switzerland, Greece, Czech Republic, Hungary, 
Poland, Portugal, Slovakia), six Asian countries (South Korea, Thailand, Indonesia, Pakistan, 
Turkey, Saudi Arabia), two South American countries (Colombia, Venezuela), two countries in 
the Oceania (Australia, New Zealand), and two African countries (Egypt, South Africa). The 
prescription data of Central America were drawn from sampled physicians in Guatemala, 
Honduras, El Salvador, Nicaragua, Costa Rica, and Panama then adjusted according to the 
stratifications to obtain six countries’ projected prescriptions. Therefore, “Central America” was 
used to represent six countries’ projected prescription data throughout this study.  
Drug prescribing 
We used several drug categories to classify ASD treatment: (1) stimulants (atomoxetine, 
dexamfetamine, methylphenidate), (2) antidepressants, (3) antipsychotics, (4) 
antiepileptics/mood stabilisers, (5) benzodiazepines, (6) sleep medications (including melatonin), 
(7) clonidine, (8) beta-blockers, (9) antiparkinson medication, and (10) anxiolytics.  
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Estimated prescription rate  
The “average annual projected number of prescriptions” was calculated by the summation of the 
projected number of prescriptions between 2007 and 2012 (inclusive); followed by the division 
of the sum by 6. The estimated annual prescription rates were calculated by dividing “average 
annual projected number of prescriptions” by the estimated annual population. The estimated 
annual population figures for each country in 2010 were obtained from the United Nations, 
Department of Economic and Social Affairs: (http://esa.un.org/wpp/excel-Data/population.htm). 
By using the average of six-year data, it can reduce random variation within the data. As noted 
above, it has been reported that people with mental health disorders receive less treatment in 
low/middle income countries compared with high income countries (MacArthur & The Academy 
of Medical Sciences, 2008). In order to investigate whether low/middle income countries is 
associated with lower ASD treatment compared to high income countries, the Gross Domestic 
Product (GDP) per capita in US dollars in 2010 was used as an indicator of each county’s living 
standard and its association with ASD treatment calculated. The GDP per capita data were 
obtained from the United Nations, National Accounts Main Aggregates Database: 
(http://unstats.un.org/unsd/snaama/dnllist.asp). For Central America, the GDP per capita was the 
mean of the sum of GDP per capita of the six countries. 
Data analysis 
We analysed the data by drug class and by individual drug for each country. Spearman 
correlation was used to investigate the association between prescription rate and GDP per capita; 
this was selected (rather than Pearson correlation) because it is less sensitive to outliers, which 
may occur in relation to GDP per capita figures. Data management and analyses were performed 
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using Microsoft Excel 2010®, Statistical Analysis System (SAS) v9.3 (SAS Inc, United States), 
and Stata MP version 11.2 (StataCorp, College Station, TX, United State).  
Results 
There was a wide range of estimated prescription rates in different countries between 2007 and 
2012 (Table 2). The European countries were found to have highest prescription rate (1.34-
36.36/10,000). The lowest prescription rates were observed in Egypt (0.74/10,000), Venezuela 
(0.83/10,000) and Asian countries such as Turkey, Saudi Arabia, Indonesia and Pakistan (0.04-
0.82/10,000).  
Figure 1 shows the proportion of different psychotropic class for ASD treatment by country 
between 2007 and 2012. Antipsychotics were the most commonly prescribed drug class for ASD 
treatment in all countries except Austria, Finland and New Zealand. In Finland, benzodiazepines 
(27.7%) and anxiolytics (22.1%) were the most commonly prescribed drug classes for ASD 
treatment. Antidepressants were the second most commonly prescribed drug class in Australia, 
South Africa and most of European countries except the Czech Republic, Hungary, Poland, 
Portugal, and Slovakia. Antiepileptics were the second most commonly prescribed drug class in 
the Czech Republic, Hungary, Poland, Portugal and Slovakia.  
There was a significant positive relation between GDP per capita and prescription rate 
(Spearman's coefficient ρ=0.60; p=0.0011 (Figure 2). In general, countries with low GDP per 
capita have low estimated prescription rates. However, it is important to note that this was not 
universally the case. For instance, some countries (e.g. Switzerland, Austria, Finland and 
Australia) have high GDP per capita but low estimated prescription rates for ASD treatment; in 
contrast Colombia and Thailand have low GDP per capita but high estimated prescription rates.  
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Table 3 shows the most common drug prescribed for ASD treatment in each country. 
Risperidone was a commonly prescribed drug in all countries except Finland. Buspirone (an 
anxiolytic) was the drug most commonly prescribed for ASD treatment in Finland. Stimulants 
(methylphenidate, atomoxetine) and anti-epileptic drugs (e.g. lamotrigine, carbamazepine, 
valproic acid) were also prescribed for treatment in most countries. 
Discussion 
There is considerable variation in prescription rates among countries. The variation of 
psychopharmacological prescription patterns may be explained by a number of factors such as 
socioeconomic status, awareness or levels of knowledge about ASD, perceptions towards ASD 
treatment and access to health services. In general, antipsychotic drugs were the most frequently 
prescribed drug class for ASD and risperidone was commonly prescribed in all countries. There 
are two FDA-approved medications (risperidone and aripiprazole) licensed for the treatment of 
irritability or aggression in patients with ASD. Risperidone is also labelled for the treatment of 
behavioural problems in people with ASD in some countries including European countries. In 
addition, as risperidone is off-patent and the generic products are more affordable than 
aripiprazole, this may explain its popularity as ASD treatment.  
Stimulants, antiepileptics, mood stabilisers, and antidepressants were also frequently prescribed 
for ASD treatment in our study. However, as we do not have the information on the individuals’ 
co-morbidities, we do not know whether these drugs are being used for the treatment of ASD 
symptoms or other psychiatric co-morbidities. Since there are very limited data on the efficacy 
and long term adverse reactions of these drugs in patients with ASD, further research is 
warranted.  
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There was significant association between psychotropic drug use for ASD treatment and GDP 
per capita. Our results indicate that in general countries with low GDP tend to have low 
prescription rates. Low prescription rates found in low/middle countries could be due to smaller 
health budgets to mental health policy and services. A study involving 191 countries reported 
that a smaller proportion of health budget was allocated to mental health in lower income 
countries compared with higher income countries. In addition, many low income countries relied 
on out-of-pocket expenditure (Saxena, Sharan, & Saraceno, 2003). In comparison to tax-based 
and insurance-based for health care financing, out-of-pocket expenditure could create financial 
burdens for the patients and their families, and thus may lower the rate of receiving services in 
the low/middle income countries. Another survey reported a similar association between the 
overall expenditures on health care and percentage of patients receiving services (Wang et al., 
2007). In 2006, the Academy of Medical Sciences showed that the limited access to mental 
health treatment among patients living in lower/middle income countries compared to higher 
income countries (MacArthur & The Academy of Medical Sciences, 2008). It also reported that 
low availability of mental health professionals in low/middle income countries may impact on 
this. For instance, there is up to a 200-fold difference between some countries in the number of 
available psychiatrists, nurses, psychologists and social workers. This means there are, on 
average, five psychiatrists per million people in low/middle income countries as compared to 40 
psychiatrists per million people in the UK. In addition to limited access to health services, 
patients who initiate treatments for mental disorders receive much less follow-up care in 
low/middle income countries as compared with high income countries (Wang et al., 2007). 
Reduced follow-up care could also contribute to the lower prescription rates in low/middle 
income countries. Further research is needed to obtain more detailed data to investigate the 
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association between ASD treatment and health care expenditures on mental health in different 
countries. 
To our knowledge, this is the largest multi-national comparison of psychopharmacological use in 
ASD treatment. However, there are notably several limitations. First, as IMS MIDAS is not a 
patient-based medical record database, we were unable to report the number of patients who 
visited physicians for ASD treatment in this study. Consequently, we cannot estimate the 
treatment rates in patients with ASD. Second, our stratified sampling was intended to provide a 
representative sample for each country. However some patients may be under the care of 
psychiatrists for the management of ASD-related symptoms and the sample of clinicians we had 
access to only represent a small percentage of psychiatrists. Therefore, the audit may have under-
estimated the number of prescriptions. Third, we were unable to obtain data on co-morbidities, 
so we do not know whether psychotropic drugs were prescribed for the treatment of core 
symptoms of ASD or for other psychiatric co-morbidities. Lastly, despite the significant positive 
correlation between GDP per capita and prescription rate for ASD treatment, potential 
confounders could not be adjusted for due to limited information in the dataset (e.g. age of the 
patients and the use of complementary/ ‘alternative’ treatments).  
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Conclusion 
There is wide variation in the psychopharmacological treatment of ASD among countries. In 
general, European countries have the highest prescription rate compared to those in Asian 
regions. Also there is an association between psychotropic drug use and GDP per capita in most 
(but not all) countries. Future research should incorporate more data including treatment rates, 
age of the patients and the use of complementary or alternative treatments for ASD in different 
countries to develop an in-depth understand of the disparity of psychopharmacological treatment 
between countries.   
 
 
Total words: 2318 
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Table 1 Method of data collection in each country 
Countries by continent No. of doctors involved in 
data collection 
Stratification of sampling 
  
Reporting time 
Europe 
  Austria 300  Region, speciality 7 consecutive days per quarter  
  Belgium 520 Region, speciality  7 consecutive days per quarter  
  Netherlands  360 Region, speciality, community size 7 consecutive days per quarter  
  Finland 16,287 Region, speciality, practice type 5 consecutive days per semester 
  Ireland 200 Region 6 consecutive days per quarter  
  Switzerland 304 Region, speciality  5 consecutive days per semester  
  Greece 474 Region, speciality  7 consecutive days per quarter  
  Czech Republic 470 Speciality  7 consecutive days per semester  
  Hungary 540 Speciality  7 consecutive days per semester  
  Poland 565 Speciality  7 consecutive days per semester  
  Portugal 679 Region, speciality  7 consecutive days per quarter  
  Slovakia 390 Speciality  7 consecutive days per semester  
Asia   
  South Korea 701 Regions, speciality, practice type 7 consecutive days per semester  
  Thailand 440 Region, speciality  7 consecutive days per semester  
  Indonesia  450 Region, speciality 7 consecutive days per semester  
  Pakistan 540 Region, speciality 7 consecutive days per semester  
  Turkey  705 Region, speciality 7 consecutive days per semester  
  Saudi Arabia 320 Region, speciality 7 consecutive days per quarter  
Central America  
Guatemala, Honduras, El  
Salvador, Nicaragua, Costa 
Rica, Panama 
740 Country, speciality  7 consecutive days per semester  
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Continue. 
Countries by continent No. of doctors involved in 
data collection 
Stratification of sampling 
  
Reporting time 
South America   
  Colombia 385  Region, speciality, practice type 7 consecutive days per semester  
  Venezuela 500 Region, speciality  7 consecutive days per semester  
Australia 
   Australia 420 Region, speciality 7 consecutive days per quarter  
   New Zealand  200 Region 7 consecutive days per quarter  
Africa  
  Egypt  525 Region, speciality 7 consecutive days per quarter 
   South Africa  384 Region, speciality, community size, 
location of general practitioner’s 
practice (metropolitan or non-
metropolitan) 
7 consecutive days per quarter  
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Table 2 Estimated prescription rates for autistic spectrum disorder (ASD) treatment in 2007-2012a 
Country  Average projected number of 
prescriptions for patients  
with ASD per year 
Estimated population in 2010b Estimated prescription rate 
(number of ASD prescriptions per 
10,000 people  
in the general public)c 
Europe 
  Austria 3,269 8,394,000 3.89 
  Belgium 34,010 10,712,000 31.75 
  Netherlands  60,400 16,613,000 36.36 
  Finland 2,150 5,365,000 4.01 
  Ireland 2,656 4,470,000 5.94 
  Switzerland 11,764 7,664,000 15.35 
  Greece 1,526 11,359,000 1.34 
  Czech Republic 4,105 10,493,000 3.91 
  Hungary 1,683 9,984,000 1.69 
  Poland 15,192 38,277,000 3.97 
  Portugal 10,690 10,676,000 10.01 
  Slovakia 3,056 5,462,000 5.59 
Asia   
  South Korea 69,184 48,184,000 14.36 
  Thailand 69,010 69,122,000 9.98 
  Indonesia  9,587 239,871,000 0.40 
  Pakistan 651 173,593,000 0.04 
  Turkey  5,941 72,752,000 0.82 
  Saudi Arabia 1389 27,448,000 0.51 
Central America    
Guatemala, Honduras, El  
Salvador, Nicaragua, Costa 
Rica, Panama 
4,924 42,146,000 1.17 
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Continue. 
Country  Average projected number of 
prescriptions for patients with 
ASD per year 
Estimated population in 2012b Estimated prescription rate 
(number of ASD prescriptions 
per 10,000 people in the general 
public)c 
South America   
  Colombia 29,678 46,295,000 6.41 
  Venezuela 2,400 28,980,000 0.83 
Oceania 
   Australia 6,103 22,268,000 2.74 
   New Zealand  3,553 4,368,000 8.13 
Africa 
Egypt 6,039 81,121,000 0.74 
   South Africa  6,631 50,133,000 1.32 
aStudy drug includes: stimulants; antidepressants; antipsychotics; antiepileptics/mood stabilises; benzodiazepines; sleep medication; 
clonidine; beta-blockers; antiparkinsonians; other anxiolytics. 
bPopulation was obtained from United Nations, Department of Economic and Social Affairs, Population Division, World Population 
Prospects. Available from http://esa.un.org/unpd/wpp/Excel-Data/population.htm. 
cNumbers presented in 2 decimal places.   
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Figure 1 Percentage of different psychotropic drug classes for the treatment of autistic spectrum disordera 
 
aCA = Central America; SA = South America.
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Figure 2 Scatter plot of estimated prescription rates for autistic spectrum disorder (ASD) treatment versus Gross Domestic 
Products (GDP) per capita in each countrya 
 
aGDP per capita at current prices in US dollars in 2010 was obtained from United Nations, National Accounts Main Aggregates Database. 
Available from http://unstats.un.org/unsd/snaama/dnllist.asp. 
Spearman's coefficient ρ=0.60;  p=0.0011 
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Table 3 Common drugs prescribed for ASD treatment in 2007-2012 
Countries by region Drug Projected number of 
prescriptions per year 
% 
Europe  
  Austria Lamotrigine 910 27.8 
 Risperidone 654 20.0 
 Atomoxetine 544 16.6 
 Total projected prescriptions 3,269 100.0 
  Belgium Risperidone 11,816 34.7 
 Aripiprazole 4,036 11.9 
 Pipamperone 2,671 7.9 
 Total projected prescriptions 34,010 100.0 
  Netherlands Risperidone 22,696 37.6 
 Aripiprazole 6,275 10.4 
 Methylphenidate 6,144 10.2 
 Total projected prescriptions 60,400 100.0 
  Finland Buspirone 451 21.0 
 Escitalopram 322 15.0 
 Oxazepam 303 14.1 
 Total projected prescriptions 2,150 100.0 
  Ireland Zuclopenthixol 497 18.7 
 Risperidone 431 16.2 
 Methylphenidate 354 13.3 
 Total projected prescriptions 2,656 100.0 
  Switzerland Risperidone 1,902 16.2 
 Aripiprazole 1,512 12.8 
 Quetiapine 905 7.7 
 Total projected prescriptions 11,764 100.0 
  Greece Olanzapine 509 33.3 
 Risperidone 241 15.8 
 Clomipramine 207 13.5 
 Venlafaxine 207 13.5 
 Total projected prescriptions 1,526 100.0 
  Czech Republic Risperidone 2,021 49.2 
 Chlorprothixene 403 9.8 
 Atomoxetine 308 7.5 
 Total projected prescriptions 4,105 100.0 
  Hungary Carbamazepine 300 17.8 
 Risperidone 296 17.6 
 Zuclopenthixol 189 11.2 
 Total projected prescriptions 1,683 100.0 
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Continue 
 
Countries by region Drug Projected number of 
prescriptions per year 
% 
  Poland Risperidone 3,657 24.1 
 Valproic acid 1,869 12.3 
 Lamotrigine 1,614 10.6 
 Total projected prescriptions 15,192 100.0 
  Portugal Risperidone 3,709 34.7 
 Methylphenidate 659 6.2 
 Valproic acid 631 5.9 
 Total projected prescriptions 10,690 100.0 
 Slovakia Risperidone 747 24.4 
 Clonazepam 347 11.4 
 Quetiapine 294 9.6 
 Total projected prescriptions 3,056 100.0 
Asia 
  South Korea Risperidone 32,792 47.4 
 Methylphenidate 4,285 6.2 
 Valproic acid 3,266 4.7 
 Total projected prescriptions 69,184 100.0 
  Thailand Risperidone 38,116 55.2 
 Valproic acid 13,496 19.6 
 Methylphenidate 5,113 7.4 
 Total projected prescriptions 69,010 100.0 
  Indonesia Risperidone 3,472 36.2 
 Aripiprazole 2,573 26.8 
 Piracetam 1,224 12.8 
 Total projected prescriptions 9,587 100.0 
  Pakistan Risperidone 651 100.0 
 Total projected prescriptions 651 100.0 
  Turkey Risperidone 4,427 74.5 
 Carbamazepine 372 6.3 
 Valproic acid 239 4.0 
 Lamotrigine 236 4.0 
 Total projected prescriptions 5,941 100.0 
  Saudi Arabia Risperidone 898 64.7 
 Carbamazepine 266 19.2 
 Piracetam 75 5.4 
 Total projected prescriptions 1,389 100.0 
Central America 
Guatemala, Honduras, El  
Salvador, Nicaragua, Costa 
Rica, Panama 
Risperidone 2,608 53.0 
 Haloperidol 432 8.8 
 Piracetam 312 6.3 
 Total projected prescriptions 4,924 100.0 
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Continue 
 
Countries by region Drug Projected number of 
prescriptions per year 
% 
South America   
  Colombia Risperidone 15,257 51.4 
  Fluoxetine 3,835 12.9 
 Aripiprazole 2,008 6.8 
 Total projected prescriptions 29,678 100.0 
  Venezuela Risperidone 789 32.9 
 Clonazepam 526 21.9 
 Atomoxetine 289 12.1 
 Total projected prescriptions 2,400 100.0 
Oceania    
   Australia Risperidone 2,859 46.8 
    Methylphenidate 552 9.0 
 Sertraline 545 8.9 
 Total projected prescriptions 6,103 100.0 
   New Zealand Methylphenidate 958 27.0 
 Risperidone 556 15.6 
 Melatonin 338 9.5 
 Total projected prescriptions 3,553 100.0 
Africa     
  Egypt  Risperidone 3,792 62.8 
   Piracetam 632 10.5 
 Carbamazepine 548 9.1 
 Total projected prescriptions 6,039 100.0 
   South Africa  Risperidone 3,158 47.6 
    Citalopram 1,688 25.5 
    Methylphenidate 924 13.9 
 Total projected prescriptions 6,631 100.0 
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Supplementary Online Material 1: The International Classification of Diseases (ICD), 
tenth version codes to identify autistic spectrum disorder (ASD) patients 
 
ICD 10  Diagnosis 
F84 
  F84.0 
Pervasive Development Disorder 
   Childhood autism 
  F84.1    Atypical autism 
  F84.2     Rett’s syndrome 
  F84.3    Other childhood disintegrative disorder 
  F84.4 Overactive disorder associated with mental retardation and   
stereotyped movements 
  F84.5    Asperger’s syndrome 
 
  F84.8 
   Other pervasive developmental disorders 
  F84.9    Pervasive developmental disorder, unspecified 
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